We are live on ! Find out more
ETC

Exchange Traded Concepts Portfolio holdings

AUM $21.9B
1-Year Est. Return 68.6%
This Fund
S&P 500
This Quarter Est. Return
-3.99%
1 Year Est. Return
+68.6%
3 Year Est. Return
+158.93%
5 Year Est. Return
+186.62%
10 Year Est. Return
–
AUM
$3.53B
AUM Growth
-$528M
Cap. Flow
-$324M
Cap. Flow %
-9.18%
Top 10 Hldgs %
29.69%
Holding
1,565
New
259
Increased
499
Reduced
543
Closed
256

Top Buys

Rank Stock Value
1
GBIL icon
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
+$365M
2
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$365M
3
EMR icon
Emerson Electric
EMR
+$25.8M
4
VDE icon
Vanguard Energy ETF
VDE
+$23.4M
5
UNH icon
UnitedHealth
UNH
+$15.7M

Top Sells

Rank Stock Value
1
BLV icon
Vanguard Long-Term Bond ETF
BLV
+$158M
2
USRT icon
iShares Core US REIT ETF
USRT
+$141M
3
XLK icon
State Street Technology Select Sector SPDR ETF
XLK
+$138M
4
VXF icon
Vanguard Extended Market ETF
VXF
+$101M
5
VGLT icon
Vanguard Long-Term Treasury ETF
VGLT
+$69.4M

Sector Composition

Rank Sector Weight
1 Technology 21.29%
2 Energy 11.87%
3 Healthcare 10.76%
4 Industrials 6.89%
5 Consumer Discretionary 5.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
901
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$99.2K ﹤0.01%
7,798
-2,005
-20% -$27.7K
IBRX icon
902
ImmunityBio
IBRX
$7.15B
$98.3K ﹤0.01%
58,136
+10,596
+22% +$21.3K
TYRA icon
903
Tyra Biosciences
TYRA
$1.85B
$98K ﹤0.01%
7,114
-1,753
-20% -$26K
ZYME icon
904
Zymeworks
ZYME
$1.62B
$97.6K ﹤0.01%
15,389
-1,139
-7% -$8.41K
THRX
905
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$97.4K ﹤0.01%
36,210
+21,419
+145% +$84K
GMAB icon
906
Genmab
GMAB
$17.5B
$97.2K ﹤0.01%
2,755
-941
-25% -$35.9K
CMPX icon
907
Compass Therapeutics
CMPX
$349M
$96.8K ﹤0.01%
49,129
+5,924
+14% +$14.6K
IDYA icon
908
IDEAYA Biosciences
IDYA
$3.43B
$96.8K ﹤0.01%
3,587
-2,063
-37% -$52.3K
KURA icon
909
Kura Oncology
KURA
$793M
$96.5K ﹤0.01%
10,581
-594
-5% -$6.03K
SWAV
910
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$96.2K ﹤0.01%
483
+50
+12% +$11.8K
MDGL icon
911
Madrigal Pharmaceuticals
MDGL
$12.6B
$95.7K ﹤0.01%
655
+487
+290% +$91.7K
VOR icon
912
Vor Biopharma
VOR
$1.06B
$95.2K ﹤0.01%
2,246
+869
+63% +$47.1K
PSMT icon
913
Pricesmart
PSMT
$5.94B
$95.1K ﹤0.01%
1,278
+616
+93% +$47.6K
CGEM icon
914
Cullinan Oncology
CGEM
$1.06B
$95.1K ﹤0.01%
10,507
-1,154
-10% -$12K
BMEA icon
915
Biomea Fusion
BMEA
$88.2M
$95K ﹤0.01%
6,903
+3,329
+93% +$60K
ACRV icon
916
Acrivon Therapeutics
ACRV
$61.2M
$94.8K ﹤0.01%
9,919
-1,790
-15% -$20.7K
PNT
917
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$94.4K ﹤0.01%
14,160
+58
+0.4% +$482
RLAY icon
918
Relay Therapeutics
RLAY
$4B
$93.9K ﹤0.01%
11,168
-899
-7% -$9.67K
MRSN
919
DELISTED
Mersana Therapeutics
MRSN
$93.6K ﹤0.01%
2,948
+2,336
+382% +$111K
OII icon
920
Oceaneering
OII
$4.64B
$93.5K ﹤0.01%
+3,634
New +$83K
RXRX icon
921
Recursion Pharmaceuticals
RXRX
$1.58B
$93.4K ﹤0.01%
12,211
-2,089
-15% -$20.8K
DPZ icon
922
Domino's
DPZ
$11.9B
$93.2K ﹤0.01%
246
+182
+284% +$70K
ITOS
923
DELISTED
iTeos Therapeutics
ITOS
$93K ﹤0.01%
8,494
-1,130
-12% -$14.4K
STRO icon
924
Sutro Biopharma
STRO
$386M
$92.9K ﹤0.01%
2,676
+115
+4% +$5.01K
NRIX icon
925
Nurix Therapeutics
NRIX
$2.45B
$92.8K ﹤0.01%
11,811
-528
-4% -$4.82K
35 36
37
38 39

Similar funds

DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Capital Fund Management (CFM)
Capital Fund Management (CFM) Paris, France $22.1B AUM 20.49% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
AM
AGF Management Toronto, Ontario, Canada $22.3B AUM 46.42% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BA
Bridgewater Associates Westport, Connecticut $22.4B AUM 34.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Exchange Traded Concepts's Q3 2023 Portfolio in Review

As of Q3 2023, Exchange Traded Concepts held 1,565 positions worth $3.53B, down 13% from $4.06B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Exchange Traded Concepts withdrew a net $324M in Q3 2023, closing 256 positions and reducing 543 holdings. Its most notable exit was Vanguard Long-Term Bond ETF, an estimated $158M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Energy and Healthcare.

Against the trend, Exchange Traded Concepts opened a new position in Goldman Sachs Access Treasury 0-1 Year ETF worth $366M.

  • Exchange Traded Concepts's largest Q3 2023 buy was Goldman Sachs Access Treasury 0-1 Year ETF: 3,652,937 shares worth $366M.
  • Exchange Traded Concepts added most to iShares 0-3 Month Treasury Bond ETF in Q3 2023, an estimated $365M increase.
  • Exchange Traded Concepts's biggest Q3 2023 reduction was National Instruments Corp, cutting an estimated $19.2M.
  • Exchange Traded Concepts fully exited Vanguard Long-Term Bond ETF in Q3 2023, selling an estimated $158M.
  • Exchange Traded Concepts's ten largest holdings make up 30% of its $3.53B portfolio in Q3 2023.
  • Exchange Traded Concepts opened 259 new positions and closed 256 in Q3 2023.
  • Exchange Traded Concepts's portfolio value fell 13% quarter-over-quarter to $3.53B.

Based on Exchange Traded Concepts's 13F filing for Q3 2023, filed 18 Oct 2023.